Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyJune 30, 2026

Trump Administration Obesity Drug Agreement Faces Implementation Issues

The Trump administration's negotiated agreement with Eli Lilly and Novo Nordisk regarding obesity medication pricing and coverage is encountering implementation problems. The deal, which was intended to expand access to GLP-1 medications while controlling costs, contains unspecified loopholes or structural issues affecting its execution. The problems impact how these high-cost medications are covered and reimbursed under federal health programs. Medicaid managed care organizations should monitor whether state programs adjust coverage policies or capitation rates in response to these federal-level complications.

Why it mattersGLP-1 medications represent one of the fastest-growing pharmacy cost drivers for Medicaid MCOs, and any federal pricing or coverage framework directly affects plan formularies, prior authorization protocols, and budget forecasting.

Pharmacy · Managed Care · Finance

Read the full article at statnews.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.